HIMS Chief Policy Officer Deborah Autor Sells $464K of Stock

Deborah Autor, Chief Policy Officer at Hims & Hers Health, Inc. (NYSE: HIMS), sold 15,396 shares of the company on June 15, 2026. The shares were sold at an average price of $30.17, totaling approximately $464,497. This transaction was not part of a pre-arranged trading plan.

What Changed in Deborah Autor's Hims & Hers Health Position

Deborah Autor's recent sale of 15,396 shares marks a significant transaction for the Chief Policy Officer. After this sale, Autor's direct holdings in the company have decreased by the same amount, reflecting a strategic decision to reduce her stake in the company.

Other Institutional Activity in Hims & Hers Health

BlackRock, Inc. trimmed its holdings in Hims & Hers Health by 236,346 shares, now holding 26,337,158 shares valued at about $546.8 million. Vanguard Portfolio Management LLC initiated a position, acquiring 10,183,813 shares worth approximately $211.4 million. Morgan Stanley significantly increased its stake by 4,959,856 shares, bringing its total to 8,889,088 shares valued at roughly $184.5 million. State Street Corp also added 154,498 shares, ending with 7,460,023 shares worth about $154.9 million.

Hims & Hers Health, Inc. Stock Up 13.5%

Shares of Hims & Hers Health traded at $31.47 on the NYSE. The company has a market cap of approximately $7.28 billion and a forward P/E ratio of 35.4. With a beta of 2.398, the stock has experienced a 52-week range between $13.74 and $70.43. Its 50-day moving average is $26.07, while the 200-day moving average stands at $33.44. The company maintains a current ratio of 1.689 and a quick ratio of 1.455, with a debt-to-equity ratio of 253.725.

Recent Earnings

Hims & Hers Health reported revenue of about $2.37 billion, reflecting a 3.8% growth. However, the company has a negative net margin of -0.56% and a return on equity of -2.66%, indicating ongoing challenges in profitability. The company is set to announce its next earnings on August 10, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to Deborah Autor's sale, several other insiders at Hims & Hers Health have made transactions. CTO Mohamed Elshenawy sold 30,040 shares at $31.50 on June 17, 2026, under a planned transaction. Chief Operating Officer Michael Chi also sold 14,027 shares at the same price on the same date, with similar planned status. Meanwhile, Chief Legal Officer Soleil Boughton sold 42,261 shares on June 15, 2026, not as part of a planned transaction.

Analysts Set New Price Targets

On May 26, 2026, B of A Securities maintained a hold rating on Hims & Hers Health with a price target of $25. Truist Securities also maintained a hold rating with a $23 target on May 22, 2026. JP Morgan, on May 12, 2026, maintained a buy rating and set a price target of $33. The consensus among analysts is to hold, with a mean target price of $26.61 based on 14 opinions.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company based in San Francisco, California. It operates a platform connecting consumers to licensed healthcare professionals across several countries, including the United States, the United Kingdom, and Canada. The company offers a range of health and wellness products, both prescription and non-prescription, focusing on areas like skincare, sexual health, and mental health. Led by CEO Andrew Dudum, the company employs around 2,442 people and continues to expand its offerings and market reach.

Bottom Line

Deborah Autor's recent sale of shares in Hims & Hers Health is part of a broader pattern of insider transactions at the company. Investors often watch insider sales for potential insights into management's view of company prospects. However, it's important to note that such sales are not necessarily indicative of negative sentiment. With a diverse portfolio and ongoing analyst interest, Hims & Hers Health remains a company to watch in the healthcare sector.